JAK1 and breast cancer: Ruxolitinib, an FDA approved JAK1/2 inhibitor was found to attenuate STAT3 phosphorylation and reduce tumor growth in tamoxifen resistant breast cancer cells [57] and is currently under clinical investigation (NCT02876302, NCT02066532, NCT03012230).